Diabetes drug company Takeda Pharmaceutical Co this week announced that it had applied for approval to market a joint diabetes treatment in the United States. The drug, which combines SYR-332 and blockbuster drug Actos, is available as a single tablet.
Actos, which will lose patent protection in America in 2011, has been a bestseller for Takeda. A spokeswoman for the company, Ayako Iwamuro, reportedly commented: “It is the world’s first drug combining alogliptin (the generic name of SYR-322) and pioglitazone (the generic name of Actos). We see this providing us with a major foothold in coping with the impact of the patent expiry for Actos.”
The earliest that the pharmaceutical company will get a decision on their drug will be in 10 months time.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…